• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P2 受体相关研究的 Geoff Burnstock 历史。

History of Geoff Burnstock's research on P2 receptors.

机构信息

School of Life Sciences, Queen's Medical Centre, University of Nottingham, NG7 2UH, United Kingdom.

出版信息

Biochem Pharmacol. 2021 May;187:114358. doi: 10.1016/j.bcp.2020.114358. Epub 2020 Dec 3.

DOI:10.1016/j.bcp.2020.114358
PMID:33279495
Abstract

Geoffrey Burnstock is a purinergic signalling legend who's discoveries and conceptualisation created and shaped the field. His scientific achievements were extraordinary and sustained. They included his demonstration that ATP can act as a neurotransmitter and hence extracellular signalling molecule, which he championed despite considerable initial opposition to his proposal that ATP acts outside of its role as an energy source inside cells. He led on purine receptor classification: initially of the P1 and P2 receptor families, then the P2X and P2Y receptor families, and then subtypes of P2X and P2Y receptors. This was achieved across several decades as he conceptualised and made sense of the emerging and growing evidence that there were multiple receptor subtypes for ATP and other nucleotides. He made discoveries about short term and long term/trophic purinergic signalling. He was a leader in the field for over 50 years. He inspired many and was a great colleague and mentor. I had the privilege of spending over 10 years (from 1985) with Geoff at the Department of Anatomy and Developmental Biology, University College London. This review is a personal perspective of some of Geoff's research on P2 receptors carried out during that time. It is a tribute to Geoff who I regarded with enormous respect and admiration.

摘要

杰弗里·巴恩斯托克是嘌呤能信号转导领域的传奇人物,他的发现和概念化开创并塑造了这个领域。他的科学成就非凡且持久。其中包括他证明了 ATP 可以作为神经递质和细胞外信号分子发挥作用,尽管他最初提出 ATP 在细胞内作为能量来源之外发挥作用的观点遭到了相当大的反对,但他仍然坚持这一观点。他率先对嘌呤受体进行了分类:最初是 P1 和 P2 受体家族,然后是 P2X 和 P2Y 受体家族,然后是 P2X 和 P2Y 受体亚型。这是在几十年的时间里完成的,因为他对不断涌现和不断增长的证据进行了概念化和理解,即 ATP 和其他核苷酸有多种受体亚型。他还发现了短期和长期/营养嘌呤能信号转导。他在这个领域的领导地位超过了 50 年。他激励了许多人,是一位伟大的同事和导师。我有幸在 1985 年至 1995 年期间在伦敦大学学院解剖学与发育生物学系与 Geoff 共事了 10 多年。这篇综述是我个人对 Geoff 在那段时间里进行的一些 P2 受体研究的看法。这是对 Geoff 的致敬,我对他充满了敬意和钦佩。

相似文献

1
History of Geoff Burnstock's research on P2 receptors.P2 受体相关研究的 Geoff Burnstock 历史。
Biochem Pharmacol. 2021 May;187:114358. doi: 10.1016/j.bcp.2020.114358. Epub 2020 Dec 3.
2
The history of the Purine Club: a tribute to Prof. Geoffrey Burnstock.嘌呤俱乐部的历史:向杰弗里·伯恩斯托克教授致敬。
Purinergic Signal. 2021 Mar;17(1):127-134. doi: 10.1007/s11302-020-09749-4. Epub 2020 Nov 9.
3
Perspectives on Geoff Burnstock as researcher, teacher and friend.作为研究者、教师和朋友的视角看杰弗里·伯恩斯托克。
Biochem Pharmacol. 2021 May;187:114395. doi: 10.1016/j.bcp.2020.114395. Epub 2020 Dec 28.
4
Purinergic signalling in the cardiovascular system-a tribute to Geoffrey Burnstock.嘌呤能信号在心血管系统中的作用——纪念杰弗里·巴恩斯多克。
Purinergic Signal. 2021 Mar;17(1):63-69. doi: 10.1007/s11302-020-09734-x. Epub 2020 Nov 5.
5
Geoffrey Burnstock - An accidental pharmacologist.杰弗里·伯斯通特——一位偶然的药理学家。
Biochem Pharmacol. 2021 May;187:114300. doi: 10.1016/j.bcp.2020.114300. Epub 2020 Oct 23.
6
The P2Y/P2X divide: How it began.P2Y/P2X 分野:起源
Biochem Pharmacol. 2021 May;187:114408. doi: 10.1016/j.bcp.2021.114408. Epub 2021 Jan 11.
7
Tribute to Prof. Geoffrey Burnstock: transition of purinergicsignaling to drug discovery.向杰弗里·伯斯通教授致敬:嘌呤能信号转导向药物发现的转变。
Purinergic Signal. 2021 Mar;17(1):3-8. doi: 10.1007/s11302-020-09717-y. Epub 2020 Aug 14.
8
Geoffrey Burnstock: most highly cited scientist.杰弗里·伯恩斯托克:被引用次数最多的科学家。
Mol Interv. 2004 Aug;4(4):192-5. doi: 10.1124/mi.4.4.2.
9
The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.靶向嘌呤受体的治疗方法的发展历程:从基础科学到临床试验。
Purinergic Signal. 2022 Dec;18(4):435-450. doi: 10.1007/s11302-022-09896-w. Epub 2022 Sep 29.
10
That was then, this is now: the development of our knowledge and understanding of P2 receptor subtypes.那是过去,现在不同了:我们对 P2 受体亚型的认识和理解的发展。
Purinergic Signal. 2021 Mar;17(1):9-23. doi: 10.1007/s11302-021-09763-0. Epub 2021 Feb 1.

引用本文的文献

1
Purinergic receptors in atherosclerosis: implications for pathophysiology and therapeutic strategies.动脉粥样硬化中的嘌呤能受体:对病理生理学和治疗策略的影响。
J Physiol Biochem. 2025 Jul 16. doi: 10.1007/s13105-025-01108-4.
2
E. B. Hershberg Award: Taming Inflammation by Tuning Purinergic Signaling.E.B. 赫什伯格奖:通过调节嘌呤能信号传导来控制炎症
Acc Chem Res. 2025 Mar 18;58(6):958-970. doi: 10.1021/acs.accounts.5c00011. Epub 2025 Mar 5.